Dr Reddy's Laboratories Total Liabilities and Share Holders Equity 2010-2024 | RDY
Dr Reddy's Laboratories total liabilities and share holders equity from 2010 to 2024. Total liabilities and share holders equity can be defined as the total of all liabilities and shareholders' equity.
- Dr Reddy's Laboratories total liabilities and share holders equity for the quarter ending September 30, 2024 was $5.563B, a 33.15% increase year-over-year.
- Dr Reddy's Laboratories total liabilities and share holders equity for 2024 was $4.65B, a 18.74% increase from 2023.
- Dr Reddy's Laboratories total liabilities and share holders equity for 2023 was $3.916B, a 1.45% increase from 2022.
- Dr Reddy's Laboratories total liabilities and share holders equity for 2022 was $3.86B, a 6.34% increase from 2021.
Dr Reddy's Laboratories Annual Total Liabilities and Share Holders Equity
(Millions of US $) |
| 2024 |
$4,650 |
| 2023 |
$3,916 |
| 2022 |
$3,860 |
| 2021 |
$3,630 |
| 2020 |
$3,081 |
| 2019 |
$3,259 |
| 2018 |
$3,465 |
| 2017 |
$3,390 |
| 2016 |
$3,134 |
| 2015 |
$3,126 |
| 2014 |
$2,837 |
| 2013 |
$2,611 |
| 2012 |
$2,348 |
| 2011 |
$2,133 |
| 2010 |
$1,787 |
| 2009 |
$1,646 |
Dr Reddy's Laboratories Quarterly Total Liabilities and Share Holders Equity
(Millions of US $) |
| 2024-09-30 |
$5,563 |
| 2024-06-30 |
$4,984 |
| 2024-03-31 |
$4,650 |
| 2023-12-31 |
$4,482 |
| 2023-09-30 |
$4,178 |
| 2023-06-30 |
$4,084 |
| 2023-03-31 |
$3,916 |
| 2022-12-31 |
$3,739 |
| 2022-09-30 |
$3,576 |
| 2022-06-30 |
$3,746 |
| 2022-03-31 |
$3,860 |
| 2021-12-31 |
$3,798 |
| 2021-09-30 |
$3,760 |
| 2021-06-30 |
$3,743 |
| 2021-03-31 |
$3,630 |
| 2020-12-31 |
$3,456 |
| 2020-09-30 |
$3,445 |
| 2020-06-30 |
$3,326 |
| 2020-03-31 |
$3,081 |
| 2019-12-31 |
$3,054 |
| 2019-09-30 |
$3,311 |
| 2019-06-30 |
$3,295 |
| 2019-03-31 |
$3,259 |
| 2018-12-31 |
$3,258 |
| 2018-09-30 |
$3,229 |
| 2018-06-30 |
$3,372 |
| 2018-03-31 |
$3,465 |
| 2017-12-31 |
$3,540 |
| 2017-09-30 |
$3,400 |
| 2017-06-30 |
$3,380 |
| 2017-03-31 |
$3,390 |
| 2016-12-31 |
$3,345 |
| 2016-09-30 |
$3,311 |
| 2016-06-30 |
$2,896 |
| 2016-03-31 |
$3,134 |
| 2015-12-31 |
$3,141 |
| 2015-09-30 |
$3,091 |
| 2015-06-30 |
$3,164 |
| 2015-03-31 |
$3,126 |
| 2014-12-31 |
$2,925 |
| 2014-09-30 |
$2,848 |
| 2014-06-30 |
$2,890 |
| 2014-03-31 |
$2,837 |
| 2013-12-31 |
$2,715 |
| 2013-09-30 |
$2,575 |
| 2013-06-30 |
$2,536 |
| 2013-03-31 |
$2,611 |
| 2012-12-31 |
$2,531 |
| 2012-09-30 |
$2,467 |
| 2012-06-30 |
$2,279 |
| 2012-03-31 |
$2,348 |
| 2011-12-31 |
$2,310 |
| 2011-09-30 |
$2,198 |
| 2011-06-30 |
$2,197 |
| 2011-03-31 |
$2,133 |
| 2010-12-31 |
$1,874 |
| 2010-09-30 |
$1,792 |
| 2010-06-30 |
$1,765 |
| 2010-03-31 |
$1,787 |
| 2009-12-31 |
$1,565 |
| 2009-09-30 |
$1,711 |
| 2009-06-30 |
$1,761 |
| 2009-03-31 |
$1,646 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$11.677B |
$3.350B |
|
Dr. Reddy's Laboratories Ltd. is an integrated global pharmaceutical company engaged in providing affordable and innovative medicines since 1984. The company markets its products in countries like the U.S., the UK, Germany, India, Russia, Venezuela, Romania and South Africa. Dr. Reddy's operates through three segments: Global Generics comprising unbranded prescription drugs along with over-the-counter drugs. It includes the operations of the company's biologics business. Pharmaceutical Services & Active Ingredients (PSAI) comprising active pharmaceutical ingredients (API) and custom pharmaceutical services. Proprietary Products and Others involving the new chemical entities, the differentiated formulations business and a dermatology specialty business. The company has a strategic partnership with Glaxo to market selected products across emerging markets outside India.
|
